One in three Asians on clopidogrel is taking a pill that may not work for them.
CYP2C19 poor metabolisers face up to 6× the risk of stent thrombosis. Most patients on this drug have never been tested. A preventable failure, written in their genome since birth.
A common epilepsy drug. A common Asian variant. A fatal skin reaction nobody saw coming.
5 to 15% of South Asians carry HLA-B*15:02 — a single allele that turns carbamazepine into Stevens‑Johnson syndrome. A simple test before the first prescription would prevent it. Most patients are never offered the test.
Most monogenic diabetes is misdiagnosed as Type 1 or Type 2. For decades. With daily insulin.
An estimated 80% of MODY cases are mistaken for the wrong disease. Patients spend a lifetime on insulin when a single oral medication would work better. The right diagnosis exists in fourteen genes, waiting to be read.
Most couples marry without knowing whether they share a genetic risk that will appear in their children.
India carries the world's highest burden of inherited disorders — thalassemia, sickle cell, SMA, cystic fibrosis. Pre-marital and pre-pregnancy carrier screening is decisive. It is also, today, almost never offered.
A genetic reaction to common anaesthesia. Onset in minutes. Detectable in advance — if anyone bothers to look.
A rare but lethal reaction triggered by routine anaesthetic agents. The susceptibility is inherited and identifiable before the patient ever reaches the operating table. It is, today, almost never screened for.
The safeguard now has a name — and a login. Rybexa is live.
Everything you've just read — the tests that should have been ordered, the variants that should have been read — delivered to clinicians as one platform. Rybexa, our clinical Genomics‑as‑a‑Service layer, is launching now at rybexa.com.